# Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

> **NCT07667400** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 120 (estimated)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- Paranasal Sinus Neoplasms
- Nasopharyngeal Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Hypopharyngeal Cancer
- Carcinoma of Larynx
- Oral Squamous Cell Carcinoma
- Salivary Gland Cancer
- Adenoid Cystic Carcinoma
- Prostate Cancer
- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** SX-682
- **DRUG:** DTX

## Key facts

- **NCT ID:** NCT07667400
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-14
- **Primary completion:** 2036-10-01
- **Final completion:** 2037-10-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667400, "Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07667400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*